Skip to Content
Merck
  • Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.

Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.

Scandinavian journal of immunology (2013-12-10)
J Pieper, S Johansson, O Snir, L Linton, M Rieck, J H Buckner, O Winqvist, R van Vollenhoven, V Malmström
ABSTRACT

Proinflammatory CD4(+) CD28(null) T cells are frequently found in the circulation of patients with rheumatoid arthritis (RA), but are less common in the rheumatic joint. In the present study, we sought to identify functional differences between CD4(+) CD28(null) T cells from blood and synovial fluid in comparison with conventional CD28-expressing CD4(+) T cells. Forty-four patients with RA, displaying a distinct CD4(+) CD28(null) T cell population in blood, were recruited for this study; the methylation status of the IFNG locus was examined in isolated T cell subsets, and intracellular cytokine production (IFN-γ, TNF, IL-17) and chemokine receptor expression (CXCR3, CCR6 and CCR7) were assessed by flow cytometry on T cells from the two compartments. Circulating CD4(+) CD28(null) T cells were significantly more hypomethylated in the CNS-1 region of the IFNG locus than conventional CD4(+) CD28(+) T cells and produced higher levels of both IFN-γ and TNF after TCR cross-linking. CD4(+) CD28(null) T cells from the site of inflammation expressed significantly more CXCR3 and CCR6 compared to their counterparts in blood. While IL-17A production could hardly be detected in CD4(+) CD28(null) cells from the blood, a significant production was observed in CD4(+) CD28(null) T cells from synovial fluid. CD4(+) CD28(null) T cells were not only found to differ from conventional CD4(+) CD28(+) T cells in the circulation, but we could also demonstrate that synovial CD4(+) CD28(null) T cells showed additional effector functions (IL-17 coproduction) as compared to the same subset in peripheral blood, suggesting an active role for these cells in the perpetuation of inflammation in the subset of patients having a CD28(null) population.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, ≥99% (HPLC and TLC)
Pricing and availability is not currently available.
Sigma-Aldrich
Brefeldin A, ≥99% (HPLC and TLC), BioXtra, for molecular biology
Pricing and availability is not currently available.
Sigma-Aldrich
Sodium azide, BioXtra
Pricing and availability is not currently available.
Sigma-Aldrich
Sodium azide, purum p.a., ≥99.0% (T)
Pricing and availability is not currently available.
Sigma-Aldrich
Sodium azide, ReagentPlus®, ≥99.5%
Pricing and availability is not currently available.
Sigma-Aldrich
Sodium azide, BioUltra, ≥99.5% (T)
Pricing and availability is not currently available.
Sigma-Aldrich
Brefeldin A, from Penicillium brefeldianum, Ready Made Solution, 10 mg/mL in DMSO
Pricing and availability is not currently available.
Sigma-Aldrich
Anti-CCR7 antibody produced in rabbit, affinity isolated antibody
Pricing and availability is not currently available.
Sigma-Aldrich
Diethyl azodicarboxylate solution, purum, ~40% in toluene (H-NMR)
Pricing and availability is not currently available.